Atomoxetine-related Takotsubo Cardiomyopathy.
J Psychiatr Pract. 2016 May;22(3):232-233
Authors: Naguy A, Al-Mutairi H, Al-Tajali A
Abstract
Many psychotropic medications target norepinephrine receptors, which can have serious cardiovascular implications, especially in the context of overdoses, polypharmacy, and high-risk populations. This article presents the case of a patient with adult attention-deficit/hyperactivity disorder who developed takotsubo cardiomyopathy subsequent to pharmacokinetic and pharmacodynamic interactions between atomoxetine, a selective norepinephrine reuptake inhibitor, and fluoxetine. Clinicians should be mindful of the potential for cardiovascular adverse effects when prescribing agents that target noradrenergic receptors.
PMID: 27123802 [PubMed – as supplied by publisher]
via http://www.ncbi.nlm.nih.gov/pubmed/27123802?dopt=Abstract
